https://www.einpresswire.com/article/635441235/phathom-pharmaceuticals-resubmits-erosive-gerd-new-drug-application-to-fda
Anticipated FDA action date in Q4 2023; if approved, combined launch for Erosive GERD and H. pylori indications planned before year end If approved, vonoprazan
new drug applicationphathom pharmaceuticalserosivegerdfda